Decentralized clinical trials (DCTs) have emerged as a transformative approach in the pharmaceutical industry, offering innovative solutions to traditional clinical trial limitations. The concept of DCTs predates the COVID-19 pandemic, with the first such trial completed by Pfizer in 2011. The FDA defines DCTs as trials executed through telemedicine and mobile/local healthcare providers, using processes and technologies that differ from the traditional model, while permitting physical contact with patients. Unlike virtual trials, DCTs allow for in-person interactions, and hybrid trials combine both in-person and virtual/remote elements. A recent study by the Trials@Home consortium emphasizes the need for standardized terminology, advocating for clear distinctions between DCTs and remote or virtual trials.
The primary motivation for DCTs is to enhance patient accessibility and participation by reducing barriers such as travel, time away from work, and additional expenses. Innovations like DCTs must be accompanied by safeguards to ensure participant safety, data integrity, and consistent measurement across trials. According to a Citeline white paper, the number of trials incorporating decentralized attributes has gradually increased, leveraging tools such as digital health technologies, electronic calendars, wearables, phone calls, and online appointments. The FDA and the European Commission (EC) have published recommendations and guidance on DCTs, acknowledging the integration of decentralized elements in clinical trials and advising the consideration of these elements individually and in combination.
From a sponsor's perspective, DCTs offer significant advantages, including cost savings, time efficiency, and streamlined patient recruitment. A Tufts Center for the Study of Drug Development report indicates that DCT methods can increase drug value by $20 million per drug when applied in Phase II and III trials. Leading sponsors such as Pfizer and Sanofi have prioritized DCTs, with Sanofi co-developing Europe's first fully remote trial, the VERKKO trial, and partnering with Science 37 for technical and mobile capabilities. Sanofi's Act for Patients initiative integrates DCTs, AI, and an integrated patient platform to modernize clinical trials, reflecting a strong commitment to patient-centric approaches.
From a patient's perspective, DCTs provide greater convenience and flexibility. Ronnie Sharpe, a participant in multiple clinical trials, highlights the benefits of DCTs, including reduced travel time and the ability to complete trial activities at home. However, Teonna Woolford, another patient participant, notes that DCTs should not be one-size-fits-all, as some patients prefer the privacy and comfort of their homes, suggesting a hybrid approach may be more effective. Savvy Cooperative's Sharpe emphasizes that DCTs are essential for patient-centric research.
Looking ahead, DCTs are expected to expand into more expansive locations, including in-home testing, retail pharmacies, and mobile sites. Sanofi's Hawkins believes DCTs can significantly reduce drug cycle times and increase trial participation, making clinical trials more accessible to a broader population. Stakeholders also highlight the sustainability benefits of DCTs, particularly in reducing the carbon footprint of clinical trials. However, Lipset cautions that the primary focus should remain on patient connection and experience, ensuring that DCTs enhance, rather than diminish, the relationship between patients and investigators.
